-
公开(公告)号:MY144927A
公开(公告)日:2011-11-30
申请号:MYPI20083604
申请日:2008-09-16
Applicant: SERVIER LAB
Inventor: NANTEUIL GUILLAUME DE , PORTEVIN BERNARD , GLOANEC PHILIPPE , PARMENTIER JEAN-GILLES , BENOIST ALAIN , RUPIN ALAIN , VERBEUREN TONY , COURCHAY CHRISTINE , SIMONET SERGE
IPC: C07D207/09
Abstract: COMPOUNDS OF FORMULA (I) : WHEREIN A REPRESENTS AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR COMPOUND CONTAINING AT LEAST ONE SALT-FORMING BASIC FUNCTION, B REPRESENTS A COMPOUDD CONTAINING AT LEAST ONE SALT- FORMING ACID FUNCTION AND AT LEAST ONE NO DONOR GROUP, M REPRESENTS THE NUMBER OF ACID FUNCTIONS OF B THAT HAVE BEEN CONVERTED TO A SALT AND N REPRESENTS THE NUMBER OF BASIC FUNCTIONS OF A THAT HAVE BEEN CONVERTED TO A SALT, THE BOND OR BONDS BETWEEN A AND B BEING OF THE IONIC TYPE.
-
公开(公告)号:AU2005201198B2
公开(公告)日:2010-11-11
申请号:AU2005201198
申请日:2005-03-18
Applicant: SERVIER LAB
Inventor: RUPIN ALAIN , PAMENTIER JEAN-GILES , VERBEUREN TONY , GLOANEC PHILLIPPE , BENOIST ALAIN , VALLEZ MARIE-ODILE , NANTEUIL GUILLAUME DE
IPC: C07D487/04 , A61K31/519 , A61P7/02 , A61P9/00 , A61P9/10 , A61P43/00
Abstract: 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds (I) are new. 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds of formula (I) are new. A : 1-oxidopyridyl substituted by the remainder of the molecule in any one of the positions 2, 3 and 4; m, n : 1 - 3; R 1H or linear or branched (1-6C)alkyl; R 2, R 3hydrogen, halogen, linear or branched (1-6C)alkyl, hydroxy, linear or branched (1-6C)acyloxy or linear or branched (1-6C)alkoxy; R 2+R 33-6C cycloalkane; R 4, R 5H; R 4+R 5benzo ring; Ar : phenyl, biphenylyl or naphthyl (optionally substituted by at least one of T 1) or 5 - 12-membered mono- or bi-cyclic aromatic group (containing 1 - 3 heteroatoms selected from O, N or S; and optionally substituted by at least one of T 1); and T 1halo, linear or branched (1-6C)alkyl (optionally substituted by hydroxy, carboxy or carbamoyl (optionally mono- or di-substituted by linear or branched (1-6C)alkyl, linear or branched (1-6C)alkoxy, hydroxy, trihalo-(1-6C)alkyl (in which the alkyl moiety is linear or branched), amino (optionally mono- or di-substituted by linear or branched (1-6C)alkyl, carboxymethoxy or carbamoylmethoxy (optionally mono- or di-N-substituted by linear or branched (1-6C)alkyl, hydroxy-(1-6C)alkyl (in which the alkyl moiety is linear or branched), alkoxyalkyl (in which the alkoxy and alkyl moieties are each linear or branched 1-6C) or pyridylalkyl (in which the alkyl moiety is linear or branched 1-6C)))). The configuration of the asymmetric centre at the alpha position with respect to the amide is (S). [Image] ACTIVITY : Antianginal; Thrombolytic; Cardiant; Vasotropic; Cardiovascular-Gen.; Antiarteriosclerotic. MECHANISM OF ACTION : Thrombin inhibitors. The inhibitory activity of 3-{[2,2-difluoro-2-(1-oxido-2-pyridyl)ethyl]amino}-4-oxo-N-[2-(2-oxo-2-{[2-(2-pyridyl)ethyl]amino}ethoxy)benzyl]-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide hydrochloride (A) was evaluated on human thrombin. The purified human fibrinogen (4 mM) was added to thrombin (0.7 nM) that had previously been incubated optionally with the inhibitor to be tested (20[deg]C, 10 minutes). Inhibitors, enzymes and substrates were diluted in the same buffer (0.01 mM phosphate buffer, pH 7.4, containing sodium chloride (0.12 M) and bovine serum albumin (0.05%)) and then distributed on a polystyrene microtitre plate in a volume of 50 mu l. The fibrin formed by the thrombin was measured using a spectrophotometer at 405 nm after 10 - 15 minutes reaction at 20[deg]C. The IC 50 value of (A) was found to be 1.4 nM.
-
公开(公告)号:DK2039682T3
公开(公告)日:2010-11-08
申请号:DK08290885
申请日:2008-09-19
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , PORTEVIN BERNARD , PARMENTIER JEAN-GILLES , BENOIST ALAIN , VERBEUREN TONY , RUPIN ALAIN , COURCHAY CHRISTINE , SIMONET SERGE , GLOANEC PHILIPPE
IPC: A61K31/385 , C07D207/09 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/4245 , A61K31/472 , C07D209/42 , C07D209/52 , C07D217/26 , C07D233/36 , C07D271/08 , C07D495/10
-
公开(公告)号:SI2039682T1
公开(公告)日:2010-10-29
申请号:SI200830064
申请日:2008-09-19
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , PORTEVIN BERNARD , GLOANEC PHILIPPE , PARMENTIER JEAN-GILLES , BENOIST ALAIN , VERBEUREN TONY , RUPIN ALAIN , COURCHAY CHRISTINE , SIMONET SERGE
IPC: A61K31/385 , C07D207/00 , A61K31/40 , A61K31/403 , A61K31/4245 , A61K31/472 , C07D209/00 , C07D217/00 , C07D233/00 , C07D271/00 , C07D495/00
-
公开(公告)号:SV2010003511A
公开(公告)日:2010-07-29
申请号:SV2010003511
申请日:2010-03-18
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , PORTEVIN BERNARD , GLOANEC PHILIPPE , PARMENTIER JEAN-GILLES , BENOIST ALAIN , VERBEUREN TONY , RUPIN ALAIN , COURCHAY CHRISTINE , SIMONET SERGE
IPC: A61K31/34 , A61K31/40 , A61K31/404 , A61K31/407 , A61K31/421 , A61K31/472 , A61P9/00 , C07D207/08 , C07D207/12 , C07D209/08 , C07D209/42 , C07D209/52 , C07D215/48 , C07D271/04 , C07D339/06 , C07D495/10 , C07F9/38
Abstract: COMPUESTOS DE FORMULA (I): (A)M. (B)N (I) EN LA QUE A REPRESENTA UN COMPUESTO INHIBIDOR DE LA ENZIMA DE CONVERSIÓN DE LA ANGIOTENSINA QUE CONLLEVA AL MENOS UNA FUNCIÓN BÁSICA SALIFICABLE, B REPRESENTA UN 10 COMPUESTO QUE CONLLEVA AL MENOS UNA FUNCIÓN ACIDA SALIFICABLE Y AL MENOS UN GRUPO DONADOR DE NO, M REPRESENTA EL NUMERO DE FUNCIONES ACIDAS SALIFICADA DE B Y N REPRESENTA EL NUMERO DE FUNCIONES BÁSICA SALIFICADAS DE A, DEBIENDO ENTENDERSE QUE EL O LOS ENLACES ENTRE A Y B SON DE TIPO IÓNICO
-
公开(公告)号:RS50547B
公开(公告)日:2010-05-07
申请号:RSP20070504
申请日:2005-03-18
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , GLOANEC PHILIPPE , PARMENTIER JEAN-GILLES , BENOIST ALAIN , RUPIN ALAIN , VALLEZ MARIE-ODILE , VERBEUREN TONY
IPC: C07D487/04 , A61K9/10 , A61K31/498 , A61K31/519 , A61P7/02 , A61P9/00 , A61P9/10 , A61P43/00
-
公开(公告)号:CA2506491C
公开(公告)日:2009-09-01
申请号:CA2506491
申请日:2005-05-05
Applicant: SERVIER LAB
Inventor: HARLEY ELIZABETH , COMBETTES MURIELLE , BENOIST ALAIN , DE NANTEUIL GUILLAUME
IPC: C07D295/18 , C07D417/12 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/04 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12
Abstract: La présente invention vise un composé de formule (I): (voir formule I) dans laquelle: ~ X1 représente un atome ou groupement choisi parmi CR4a R4b, O, S(O)q1 et NR5, OU R4a, R4b, q1 et R5 sont tels que définis dans la description, ~ m1 représente zéro ou un entier compris entre 1 et 4 inclus, ~ m2 représente un entier compris entre 1 et 4 inclus, ~ n1 et n2, identiques ou différents, représentent chacun un entier compris entre 1 et 3 inclus, ~ R1 représente un atome d'hydrogène ou un groupement choisi parmi carboxy, alkoxycarbonyle, carbamoyle éventuellement substitué et alkyle éventuellemen t substitué, ~ R2 représente un atome d'hydrogène ou un groupement alkyle, ~ Ak représente une chaîne alkylène éventuellement substituée, ~ p représente zéro, 1 ou 2, ~ R3 représente un atome d'hydrogène ou un groupement cyano, ~ X2 et X3, identiques ou différents, représentent chacun, soit un groupemen t S(O)q2, soit un groupement CR6a R6b, où q2, R6a et R6b sont tels que définis dans la description, ses isomères optiques lorsqu'ils existent, ainsi que ses sels d'addition à u n acide pharmaceutiquement acceptable. L'invention s'étend à l'utilisation de ces composés, aux compositions pharmaceutiques qui les contiennent ainsi qu'à leurs procédés de préparation.
-
公开(公告)号:ES2296104T3
公开(公告)日:2008-04-16
申请号:ES05290599
申请日:2005-03-18
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , GLOANEC PHILIPPE , PARMENTIER JEAN-GILLES , BENOIST ALAIN , RUPIN ALAIN , VALLEZ MARIE-ODILE
IPC: C07D487/04 , A61K31/498 , A61K31/519 , A61P7/02 , A61P9/00 , A61P9/10 , A61P43/00
Abstract: Compuesto de fórmula (I): donde: * representa un grupo 1-óxido-piridinilo sustituido con el resto de la molécula en una cualquiera de las posiciones 2, 3 ó 4, * m y n, idénticos o diferentes, representan cada ambos un número entero comprendido entre 1 y 3, * R1 representa un átomo de hidrógeno o un grupo alquilo(C1-C6) lineal o ramificado, * R2 y R3, idénticos o diferentes, representan ambos un átomo o grupo seleccionado de entre átomos de hidrógeno y de halógeno y de entre los grupos alquilo(C1-C6) lineal o ramificado, hidroxilo, aciloxi(C1-C6) lineal o ramificado y alcoxi(C1-C6) lineal o ramificado, o forman, junto con el átomo de carbono que los porta, un cicloalcano de 3 a 6 átomos de carbono, * R4 y R5 representan ambos un átomo de hidrógeno, o son adyacentes y forman, junto con los átomos de carbono que los portan, un ciclo benzo, * Ar representa un grupo arilo o heteroarilo, sus enantiómeros, así como sus sales de adición de un ácido farmacéuticamente aceptable.
-
公开(公告)号:PL1593682T3
公开(公告)日:2008-03-31
申请号:PL05290599
申请日:2005-03-18
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , GLOANEC PHILIPPE , PARMENTIER JEAN-GILLES , BENOIST ALAIN , RUPIN ALAIN , VALLEZ MARIE-ODILE , VERBEUREN TONY
IPC: C07D487/04 , A61K31/498 , A61K31/519 , A61P7/02 , A61P9/00 , A61P9/10 , A61P43/00
-
公开(公告)号:HRP20070376T3
公开(公告)日:2007-12-31
申请号:HRP20070376
申请日:2007-09-03
Applicant: SERVIER LAB
Inventor: NANTEUIL GUILLAUME DE , BENOIST ALAIN , COMBETTES MURIELLE , HARLEY ELIZABETH
IPC: C07D295/18 , C07D405/12 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D409/12 , C07D417/12
Abstract: Spiro-cycloalkyl N-acyl pyrrolidine or thiazolidine derivatives (I), their optical isomers and acid addition salts are new. Spiro-cycloalkyl N-acyl pyrrolidine or thiazolidine derivatives of formula (I), and their optical isomers and acid addition salts, are new. X 1CR 4aR 4b, O, S(O) q1 or NR 5; R 4a and R 4bhydrogen or 1-6 C linear or branched alkyl or together complete a 3-7C cycloalkyl; q1 : 0-2; R 5hydrogen or 1-6C linear or branched alkyl, optionally substituted by hydroxy; m1 : 0-4; m2 : 1-4; n1 and n2 : 1-3; R 1hydrogen, carboxy, 1-6C linear or branched alkoxycarbonyl, carbamoyl (optionally substituted by 1 or 2 1-6C linear or branched alkyl), or 1-6C linear or branched alkyl (optionally substituted by hydroxy) or amino (optionally substituted by 1 or 2 1-6C linear or branched alkyl); R 2hydrogen or 1-6C linear or branched alkyl; Ak : 1-4C linear or branched alkylene, optionally substituted by one or more halo, particularly fluoro; p : 0-2; R 3hydrogen or cyano; X 2 and X 3S(O) q2 or CR 6aR 6b; R 6a and R 6bhydrogen or halo, preferably fluoro, or R 6a = hydrogen and R 6b = hydroxy; and q2 : 0-2. An independent claim is also included for the preparation of (I). [Image] ACTIVITY : Antidiabetic; Anorectic. MECHANISM OF ACTION : Inhibition of dipeptidyl-peptidase IV (DPPIV). The compound (2S)-1-({[9-(hydroxymethyl)-3-oxaspiro[5,5]undec-9-yl]amino}acetyl)-2-pyrrolidinecarbonitrile had IC 50 76.1 nM against porcine renal DPPIV, in an assay based on cleavage of Gly-Pro-p-nitroanilide.
-
-
-
-
-
-
-
-
-